Moderna expands global footprint through commercial partnership with adium in latin america

Moderna has a commercial footprint in 56 countries across the world through direct presence and distributors and plans expansion in ten additional markets in 2022 moderna also supplies the company's covid-19 vaccine to 92 gavi covax advance market commitment (amc) low- and middle-income countries through gavi, the vaccine alliance agreement cambridge, ma / accesswire / february 22, 2022 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines today announced a distribution service agreement with adium pharma s.a., a leading private latin american pharmaceutical company, to support the commercialization of the moderna covid-19 vaccine, spikevax across latin america.
MRNA Ratings Summary
MRNA Quant Ranking